Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer

A phase I study

H. Safran, T. P. King, H. Choy, P. J. Hesketh, B. Wolf, E. Altenhein, W. Sikov, A. Rosmarin, W. Akerley, K. Radie-Keane, G. Cicchetti, F. Lopez, K. Bland, H. J. Wanebo

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and potential antitumor activity of weekly paclitaxel with concurrent radiation (RT) for locally advanced pancreatic and gastric cancer. Patients and Methods: Thirty-four patients with locally advanced adenocarcinoma of the pancreas or stomach were studied. The initial dose of paclitaxel was 30 mg/m2 by 3-hour intravenous (IV) infusion repeated every week for 6 weeks with 50 Gy RT. Doses were escalated at 10-mg/m2 increments in successive cohorts of three new patients until dose-limiting toxicity was observed. Results: The dose-limiting toxicities at 60 mg/m2/wk were abdominal pain within the RT field, nausea, and anorexia. Of 23 patients with assessable disease, 11 (seven with gastric, four with pancreatic cancer) had objective responses for an overall response rate of 48%. Conclusion: Concurrent paclitaxel with upper abdominal RT is well tolerated at dosages that have substantial activity. A phase II trial of neoadjuvant paditaxel and RT at the MTD of 50 mg/m2/wk is underway.

Original languageEnglish (US)
Pages (from-to)901-907
Number of pages7
JournalJournal of Clinical Oncology
Volume15
Issue number3
StatePublished - Mar 1997

Fingerprint

Paclitaxel
Pancreatic Neoplasms
Stomach Neoplasms
Radiation
Maximum Tolerated Dose
Stomach
Radiation Dosage
Anorexia
Intravenous Infusions
Nausea
Abdominal Pain
Pancreas
Adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Safran, H., King, T. P., Choy, H., Hesketh, P. J., Wolf, B., Altenhein, E., ... Wanebo, H. J. (1997). Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A phase I study. Journal of Clinical Oncology, 15(3), 901-907.

Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer : A phase I study. / Safran, H.; King, T. P.; Choy, H.; Hesketh, P. J.; Wolf, B.; Altenhein, E.; Sikov, W.; Rosmarin, A.; Akerley, W.; Radie-Keane, K.; Cicchetti, G.; Lopez, F.; Bland, K.; Wanebo, H. J.

In: Journal of Clinical Oncology, Vol. 15, No. 3, 03.1997, p. 901-907.

Research output: Contribution to journalArticle

Safran, H, King, TP, Choy, H, Hesketh, PJ, Wolf, B, Altenhein, E, Sikov, W, Rosmarin, A, Akerley, W, Radie-Keane, K, Cicchetti, G, Lopez, F, Bland, K & Wanebo, HJ 1997, 'Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A phase I study', Journal of Clinical Oncology, vol. 15, no. 3, pp. 901-907.
Safran, H. ; King, T. P. ; Choy, H. ; Hesketh, P. J. ; Wolf, B. ; Altenhein, E. ; Sikov, W. ; Rosmarin, A. ; Akerley, W. ; Radie-Keane, K. ; Cicchetti, G. ; Lopez, F. ; Bland, K. ; Wanebo, H. J. / Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer : A phase I study. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 3. pp. 901-907.
@article{1a4ca8e3f95d4301bc40ee2f1f03682d,
title = "Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A phase I study",
abstract = "Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and potential antitumor activity of weekly paclitaxel with concurrent radiation (RT) for locally advanced pancreatic and gastric cancer. Patients and Methods: Thirty-four patients with locally advanced adenocarcinoma of the pancreas or stomach were studied. The initial dose of paclitaxel was 30 mg/m2 by 3-hour intravenous (IV) infusion repeated every week for 6 weeks with 50 Gy RT. Doses were escalated at 10-mg/m2 increments in successive cohorts of three new patients until dose-limiting toxicity was observed. Results: The dose-limiting toxicities at 60 mg/m2/wk were abdominal pain within the RT field, nausea, and anorexia. Of 23 patients with assessable disease, 11 (seven with gastric, four with pancreatic cancer) had objective responses for an overall response rate of 48{\%}. Conclusion: Concurrent paclitaxel with upper abdominal RT is well tolerated at dosages that have substantial activity. A phase II trial of neoadjuvant paditaxel and RT at the MTD of 50 mg/m2/wk is underway.",
author = "H. Safran and King, {T. P.} and H. Choy and Hesketh, {P. J.} and B. Wolf and E. Altenhein and W. Sikov and A. Rosmarin and W. Akerley and K. Radie-Keane and G. Cicchetti and F. Lopez and K. Bland and Wanebo, {H. J.}",
year = "1997",
month = "3",
language = "English (US)",
volume = "15",
pages = "901--907",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer

T2 - A phase I study

AU - Safran, H.

AU - King, T. P.

AU - Choy, H.

AU - Hesketh, P. J.

AU - Wolf, B.

AU - Altenhein, E.

AU - Sikov, W.

AU - Rosmarin, A.

AU - Akerley, W.

AU - Radie-Keane, K.

AU - Cicchetti, G.

AU - Lopez, F.

AU - Bland, K.

AU - Wanebo, H. J.

PY - 1997/3

Y1 - 1997/3

N2 - Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and potential antitumor activity of weekly paclitaxel with concurrent radiation (RT) for locally advanced pancreatic and gastric cancer. Patients and Methods: Thirty-four patients with locally advanced adenocarcinoma of the pancreas or stomach were studied. The initial dose of paclitaxel was 30 mg/m2 by 3-hour intravenous (IV) infusion repeated every week for 6 weeks with 50 Gy RT. Doses were escalated at 10-mg/m2 increments in successive cohorts of three new patients until dose-limiting toxicity was observed. Results: The dose-limiting toxicities at 60 mg/m2/wk were abdominal pain within the RT field, nausea, and anorexia. Of 23 patients with assessable disease, 11 (seven with gastric, four with pancreatic cancer) had objective responses for an overall response rate of 48%. Conclusion: Concurrent paclitaxel with upper abdominal RT is well tolerated at dosages that have substantial activity. A phase II trial of neoadjuvant paditaxel and RT at the MTD of 50 mg/m2/wk is underway.

AB - Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and potential antitumor activity of weekly paclitaxel with concurrent radiation (RT) for locally advanced pancreatic and gastric cancer. Patients and Methods: Thirty-four patients with locally advanced adenocarcinoma of the pancreas or stomach were studied. The initial dose of paclitaxel was 30 mg/m2 by 3-hour intravenous (IV) infusion repeated every week for 6 weeks with 50 Gy RT. Doses were escalated at 10-mg/m2 increments in successive cohorts of three new patients until dose-limiting toxicity was observed. Results: The dose-limiting toxicities at 60 mg/m2/wk were abdominal pain within the RT field, nausea, and anorexia. Of 23 patients with assessable disease, 11 (seven with gastric, four with pancreatic cancer) had objective responses for an overall response rate of 48%. Conclusion: Concurrent paclitaxel with upper abdominal RT is well tolerated at dosages that have substantial activity. A phase II trial of neoadjuvant paditaxel and RT at the MTD of 50 mg/m2/wk is underway.

UR - http://www.scopus.com/inward/record.url?scp=0031044606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031044606&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 901

EP - 907

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -